1-3 of 3
Alun D. Hughes
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Meeting Abstracts

490-P: Renal Effects of Metformin in Type 1 Diabetes (T1D): The REMOVAL Trial

JOSEPH G. TIMMONS, NICOLA GREENLAW, COEN D. STEHOUWER, MARTIJN BROUWERS, NISHI CHATURVEDI, ALUN D. HUGHES, IRENE HRAMIAK, ALICIA JENKINS, PAUL WELSH, NAVEED SATTAR, HELEN M. COLHOUN, PETER ROSSING, JOHN R. PETRIE
Journal: Diabetes
Diabetes 2020;69(Supplement_1):490-P
https://doi.org/10.2337/db20-490-P
Published: 01 June 2020
View articletitled, 490-P: Renal Effects of Metformin in Type 1 Diabetes (T1D): The REMOVAL Trial
Meeting Abstracts

456-P: The REMOVAL Trial: Effect of Metformin on Markers of Cardiometabolic Risk in Patients with Type 1 Diabetes

PAUL WELSH, NICOLA GREENLAW, HELEN COLHOUN, NISHI CHATURVEDI, IAN FORD, IRENE HRAMIAK, ALUN D. HUGHES, ALICIA JENKINS, BARBARA E.K. KLEIN, RONALD KLEIN, MARTIJN BROUWERS, PETER ROSSING, COEN D. STEHOUWER, NAVEED SATTAR, JOHN R. PETRIE, THE REMOVAL INVESTIGATORS
Journal: Diabetes
Diabetes 2019;68(Supplement_1):456-P
https://doi.org/10.2337/db19-456-P
Published: 01 June 2019
View articletitled, 456-P: The REMOVAL Trial: Effect of Metformin on Markers of Cardiometabolic Risk in Patients with Type 1 Diabetes
Journal Articles

Circulating MicroRNA-122 Is Associated With the Risk of New-Onset Metabolic Syndrome and Type 2 Diabetes

Peter Willeit, Philipp Skroblin, Alexander R. Moschen, Xiaoke Yin, Dorothee Kaudewitz, Anna Zampetaki, Temo Barwari, Meredith Whitehead, Cristina M. Ramírez, Leigh Goedeke, Noemi Rotllan, Enzo Bonora, Alun D. Hughes, Peter Santer, Carlos Fernández-Hernando, Herbert Tilg, Johann Willeit, Stefan Kiechl, Manuel Mayr
Journal: Diabetes
Diabetes 2017;66(2):347–357
https://doi.org/10.2337/db16-0731
Published: 29 November 2016
View articletitled, Circulating MicroRNA-122 Is Associated With the Risk of New-Onset Metabolic Syndrome and Type 2 Diabetes
Open the PDF for Circulating MicroRNA-122 Is Associated With the Risk of New-Onset Metabolic Syndrome and Type 2 Diabetes in another window
Includes: Supplementary data